Previous close | 3.5000 |
Open | N/A |
Bid | 2.0000 |
Ask | 2.8500 |
Strike | 18.00 |
Expiry date | 2024-10-18 |
Day's range | 3.5000 - 3.5000 |
Contract range | N/A |
Volume | |
Open interest | 6 |
Key Insights Given the large stake in the stock by institutions, Arrowhead Pharmaceuticals' stock price might be...
PASADENA, Calif., September 23, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also plans to file for regulatory clearance before the end of 2024 to initiate a clinical trial for its second obesity candidate, ARO-ALK7.
PASADENA, Calif., September 10, 2024--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to investigational plozasiran as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a severe and rare genetic disease characterized by extremely high triglyceride levels which can cause acute and potentially fatal pancreatitis. There are currently